Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 18/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880129 | 1.00 | FGFR3 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL22348768 | 0.95 | FGFR3 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL30880127 | 0.95 | FGFR3 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL30880126 | 0.93 | FGFR3 (0.50) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL29200981 | 0.93 | FGFR3 (0.50) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL22348673 | 0.91 | FGFR4 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL22348762 | 0.91 | FGFR4 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL30880149 | 0.91 | FGFR4 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL30880141 | 0.91 | FGFR4 (0.49) | FGFR3FGFR2FGFR4FGFR1 | |
| SCHEMBL22348695 | 0.90 | FGFR3 (0.50) | FGFR3FGFR2FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795256-B | FGFR inhibitors for treatment of cancer | 布里奇恩生物科学公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20220218703-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRIDGENE BIOSCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3923947-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | Bridgene Biosciences, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113795256-A | FGFR inhibitors for the treatment of cancer | 布里奇恩生物科学公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2020168237-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRIDGENE BIOSCIENCES, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218703-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | FGFR4, FGFR2, FGFR1 | FGFR3 4/4885FGFR2 2/4885FGFR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.